Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-12-19

FDA Approved: PRISTIQ EXTENDED-RELEASE — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)

View source ↗

Summary

FDA approved a supplemental application to introduce an extended-release formulation of Pristiq (desvenlafaxine succinate) from Wyeth Pharmaceuticals, a Pfizer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PRISTIQ EXTENDED-RELEASE (Desvenlafaxine succinate)

Snippet

SUPPL AP for PRISTIQ EXTENDED-RELEASE (DESVENLAFAXINE SUCCINATE)